Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO Sells $1,382,400.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHCGet Free Report) CEO John E. Kao sold 90,000 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $15.36, for a total value of $1,382,400.00. Following the transaction, the chief executive officer now directly owns 2,093,100 shares in the company, valued at approximately $32,150,016. This represents a 4.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Alignment Healthcare Price Performance

ALHC opened at $15.79 on Friday. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 1.82. Alignment Healthcare, Inc. has a 12 month low of $4.46 and a 12 month high of $16.25. The company has a fifty day simple moving average of $14.38 and a 200 day simple moving average of $12.43. The stock has a market cap of $3.03 billion, a P/E ratio of -20.51 and a beta of 1.49.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ALHC. JPMorgan Chase & Co. upped their price objective on Alignment Healthcare from $14.00 to $17.00 and gave the stock a “neutral” rating in a report on Thursday, March 6th. Piper Sandler upped their price objective on Alignment Healthcare from $14.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. Bank of America upped their price objective on Alignment Healthcare from $15.50 to $18.50 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Barclays upped their price objective on Alignment Healthcare from $8.00 to $9.00 and gave the stock an “underweight” rating in a report on Friday, February 28th. Finally, Stifel Nicolaus upped their price objective on Alignment Healthcare from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.83.

Read Our Latest Analysis on ALHC

Institutional Trading of Alignment Healthcare

A number of large investors have recently made changes to their positions in ALHC. R Squared Ltd bought a new stake in shares of Alignment Healthcare in the 4th quarter valued at $55,000. RiverPark Advisors LLC bought a new stake in shares of Alignment Healthcare in the 4th quarter valued at $106,000. Tower Research Capital LLC TRC increased its position in shares of Alignment Healthcare by 146.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company’s stock valued at $119,000 after buying an additional 6,286 shares in the last quarter. Ballentine Partners LLC bought a new stake in shares of Alignment Healthcare in the 4th quarter valued at $121,000. Finally, Aigen Investment Management LP bought a new stake in shares of Alignment Healthcare in the 4th quarter valued at $129,000. Institutional investors own 86.19% of the company’s stock.

Alignment Healthcare Company Profile

(Get Free Report)

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.

Featured Articles

Insider Buying and Selling by Quarter for Alignment Healthcare (NASDAQ:ALHC)

Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.